文献速递肾小球疾病

补体、炎症与纤维化生物标志物在自身免疫性肾小球肾炎中的临床应用

Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis.
PubMed 文献 · Kidney Int Rep · 2020-07-23

该前瞻性队列纳入100例FSGS、MN、IgAN、LN、AAV和MPGN患者,随访33(18-54)个月,重复检测尿sC5b-9、MCP-1和TGF-β1(以肌酐比值表示)。结果显示这些生物标志物在各类疾病中均可检出,与疾病活动度平行;尿sC5b-9在免疫学缓解和复发方面比蛋白尿更敏感,随访期间平均水平低于ROC确定阈值的患者肾脏结局更好。

要点

  • 尿sC5b-9、MCP-1和TGF-β1在多种自身免疫性肾小球疾病中可检出并与活动度平行。
  • 尿sC5b-9下降91%大于蛋白尿下降76%,提示其更敏锐反映免疫学缓解。
  • 随访平均生物标志物水平低于ROC阈值的患者肾脏结局更好。

核心结论

  • 在自身免疫性肾小球疾病中,尿sC5b-9、MCP-1和TGF-β1可检出并与疾病活动和结局平行。
  • 尿sC5b-9似乎是免疫学缓解和复发更敏锐的标志物。

研究设计与样本

  • 前瞻性队列研究,纳入100例FSGS、MN、IgAN、LN、AAV和MPGN患者,随访33(18-54)个月。
  • 随访期间重复收集尿液样本,检测蛋白尿及尿sC5b-9、MCP-1、TGF-β1(以肌酐比值表示)。
  • 基于各病种现行缓解定义,识别出177个活动期和非活动期。

主要发现

  • 尿sC5b-9、MCP-1和TGF-β1在每种疾病中均可检出。
  • 在走向缓解的时期,尿sC5b-9下降91%,大于蛋白尿下降76%。
  • 非活动期未复发者生物标志物水平低于复发者;复发时尿sC5b-9升高8.5倍,大于蛋白尿升高3.2倍及尿MCP-1和TGF-β1。
  • 随访期间平均生物标志物水平低于ROC确定阈值的个体肾脏结局更好。

关键数值与推荐

  • 使用各病种现行缓解定义,通过受试者工作特征曲线确定每种生物标志物的阈值。

临床怎么用

  • 尿sC5b-9、MCP-1和TGF-β1可辅助评估自身免疫性肾小球疾病活动度,补充蛋白尿信息。
  • 尿sC5b-9可能有助于识别免疫学缓解和预测复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Complement activation, inflammation, and fibrosis play central roles in the mechanisms of injury in autoimmune glomerulonephritis (GN) but they are seldom assessed in epidemiologic studies. The measurement of urinary biomarkers of these pathways of injury could parallel disease activity and add clinical value beyond proteinuria. METHODS: We performed a prospective cohort study of 100 patients with focal and segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), IgA nephropathy (IgAN), lupus nephritis (LN), anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV), and membranoproliferative GN (MPGN) followed for 33 (18-54) months. Repeated urinary samples were collected throughout their follow-up to determine proteinuria, urinary sC5b-9, monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor-beta 1 (TGF-β1), expressed as creatinine ratios. We identified 177 periods of active and inactive disease based on current remission definitions for each disease. RESULTS: Urinary sC5b-9, MCP-1, and TGF-β1 were present in each disease. In periods leading to a remission, the reduction of urinary sC5b-9 was 91%, greater than for proteinuria with 76%. During inactive periods, those who did not experience a relapse maintained lower levels of biomarkers compared with those who relapsed. At that time, the increase in urinary sC5b-9 was significantly greater than the rise in proteinuria (8.5-fold increase compared with 3.2-fold) and urinary MCP-1 and TGF-β1. Using current remission definitions for each disease, thresholds for each biomarker were determined using receiver operating characteristic curves. Individuals who averaged levels below these cutoffs during their follow-up had better renal outcomes. CONCLUSION: In autoimmune glomerular diseases, urinary sC5b-9, MCP-1, and TGF-β1 are present and parallel disease activity and outcomes. Urinary sC5b-9 appears to be a more discerning marker of immunologic remissions and relapses.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Khalili M, Bonnefoy A, Genest DS, et al. Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis. Kidney Int Rep. 2020. PMID: 33102961. doi:10.1016/j.ekir.2020.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。